Pathalys Pharma Secures $105 Million Series B Financing

Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet RESEARCH TRIANGLE PARK, NC – August 20, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round. The oversubscribed financing was led by TCGX …